Chad Carr, the grandson of a famous University of Michigan football coach, Lloyd Carr, died of a brain tumor at the age of 5. With a bad fall and a suspected concussion, doctors ran a CT scan to discover an inoperable brain tumor called diffuse intrinsic pontine glioma (DIPG). As Carr fought hard, his family virtually made DIPG known internationally: #ChadTough. Through this spread of awareness, the University of Michigan Chad Carr Pediatric Brain Tumor Center was able to be established (Michigan Medicine). Another case, Senator John McCain, a war hero, a U.S. senator, and a 2008 presidential candidate, died of a brain tumor called glioblastoma (GBM) at the age of 81. A CT scan helped to connect the senator’s inexplicable symptoms of fatigue, brain fog, and double vision. After more than a year of fighting the cancer, he made the decision to stop treatment in 2017. A day later he passed away (CNN). There is a great chance that you may have heard of either of these people and their tribulations with their horrific diseases. And, despite the fact that DIPGs and GBMs are rare, they both share one commonality: they possess the ability to rapidly progress and debilitate the patient, even in the face of treatment (Johns Hopkins Medicine). So, what exactly gives these conditions their notorious reputations and what does the future of medicine hold in stopping these diseases in their tracks?